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Controlled plasma exchange trial in acute renal failure due to
multiple myeloma
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Department of Nephrology, Malpighi Hospital, U.S. L. 28 Bologna North, Bologna, Italy
Controlled plasma exchange trial in acute renal failure due to multiple
myeloma. We studied 29 patients affected by acute renal failure due to
multiple myeloma with Bence-Jones proteinuria > I g/clay to evaluate
the effectiveness of plasma exchange in the treatment of severe myelo-
ma nephropathy. Renal failure was severe enough to require dialysis in
24 cases, while the remaining 5 patients showed serum creatinine levels
greater than 5 mg/dl. The patients were randomly allocated to Group 1
(15 patients undergoing plasma exchange together with corticosteroids,
cytotoxic drug, hemodialysis only when needed) or to Group II (14
patients undergoing peritoneal dialysis together with corticosteroids
and cytotoxic drug). In Group 1 Bence-Jones proteinuria decreased
dramatically (P < 0.01) with a significant increase in urine output (P <
0.001), while Group II presented a slight reduction in Bence-Jones
proteinuria without a significant increase in daily diuresis. Thirteen out
the 15 Group 1 patients recovered renal function reaching serum
creatinine levels 2.5 mg/dI in most cases. Only two patients in Group
II improved renal failure well enough to stop dialysis. The one-year
survival rate was significantly higher in Group 1(66%) than in Group 11
(28%, P < 0.01). We conclude that plasma exchange associated to
chemotherapy rapidly removes large amounts of light chains, improves
both renal function and long-term survival expectancies.
Renal insufficiency occurs in over 50% of multiple myeloma
(MM) patients [1, 2] and it is usually held to be an ominous
complication [3]. The reported mean survival of MM patients
with severe renal failure varies between 2 and 13 months, in
spite of using dialysis and chemotherapy [3, 4]. A recent
retrospective study by Cosio et al. [5] reported a 53% one year
survival in 34 MM patients undergoing chronic dialysis. Numer-
ous factors are involved in kidney damage (such as hypercal-
cemia, plasma cell infiltration, plasma hyperviscosity, dehydra-
tion. etc.) but clinical, experimental and morphological studies
[6, 7] suggest that light chains per se may play a dominant role.
Plasma exchange (PE) has recently been thought to be the
most efficient way to rapidly remove large amounts of light
chains, so it is recommended in managing severe renal insuffi-
ciency in association with forced alkaline diuresis, dialysis and
chemotherapy [8—10].
In order to assess the effectiveness of PE in treating severe
myeloma nephropathy we examined 29 patients with acute
renal failure due to MM in a controlled study.
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Methods
Patients
From 1980 to 1986 twenty-nine consecutive patients were
referred to our Renal Service with acute renal failure caused by
previously or subsequently recognized MM. They included 21
males and 8 females who were 48 to 73 years old, with a mean
age of 63 years. All the patients were either followed up to death
or up to December 1986. The MM diagnosis was based on the
presence of marrow plasmocytosis in sheets or clusters involv-
ing more than 15% of the cells and on the discovery of
monoclonal paraprotein in serum and/or urine. In 19 patients,
all with light chain myeloma, MM was diagnosed after the
occurrence of progressive renal failure, while in the remaining
10 patients the underlying disease was known 2 to 14 months
before the onset of renal failure. Eight of these 10 patients had
previously been treated with cytotoxic drugs. No patient took
any nephrotoxic or chemotherapeutic drugs for at least two
months prior to renal failure. The criteria for admission to the
trial was the presence of acute renal failure due to MM. The
acute nature of the renal failure was defined by: a) a rapid rise
in serum creatinine to 5 mg/dl or more, not reversible by a
correction of volume status, urinary tract obstruction or any
other extra-renal abnormalities; b) previous findings of normal
or near-normal serum creatinine or blood urea nitrogen (BUN)
and; c) normal kidneys or increased size [II]. None of the
patients had any severe infections, dehydration, hyperviscosity
or a worsening of renal function following intravenous urogra-
phy. Clinical stratification of MM was done according to Dune
and Salmon's method [12] and with serum /32-microglobulin
level (I2 M).
Renal biopsies were performed on 17 patients and the renal
histologic patterns were classified as outlined in our previous
study [13].
A/fe thod.c
Complete blood counts, coagulation studies, uric acid, creat-
mine and BUN concentrations were evaluated using standard
laboratory methods. Serum protein electrophoresis was per-
formed on cellulose acetate membrane. Immunoelectrophoresis
with monospecific antisera to gamma, alpha, Mu, kappa and
lambda chains was also carried out. Electrophoresis and im-
munoelectrophoresis were performed on urine concentrated 5
to 100 times by ultrafiltration and then quantitated with the
biuret method. Tumor cell mass was calculated for each case
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using the clinical staging system introduced by Dune and
Salmon [12].
The quantitative determination of serum M was done by
solid phase enzyme immunoassay (Behring, Ingeiheim, FRG).
The normal range for this assay in subjects 40 to 79 years old
ranged from 1.2 to 3.0 mg/liter.
Treatment protocol
Immediately after diagnosis the patients were treated with
furosemide 500 to 1,500 mg/daily, 2 to 5 liters daily of intrave-
nous saline, and oral sodium bicarbonate to render the urine
neutral. When renal function did not rapidly improve and/or a
high fluid intake was not tolerated, the patients were randomly
allocated from a table of random numbers to group I (PE,
corticosteroids, cytotoxic drug and hemodialysis when needed)
or to group 11 (penitoneal dialysis, corticosteroids and cytotoxic
drug).
Acute treatment. Acute treatment consisted of methyipred-
nisolone pulse (20 mg/kg/day) given intravenously for 20 to 30
minutes on three consecutive days, followed by a course of oral
prednisone at a dosage of 20 to 30 mg/m2/day for seven days
together with cyclophosphamide 200 mg/m2/day given intrave-
nously for five days. In the event of myelotoxicity a one day
reduction in the cyclophosphamide course was permitted. In
every group I patient five PE sessions were performed on five
consecutive days, while in some cases an additional PE was
performed on seventh and tenth days, using the femoral veins
for vascular access in all cases. Polypropylene plasma filters
were used (Plasmex FF20, 0.2 m2) and about 3 to 4 liters of each
patient's plasma was removed at each session. This plasma was
replaced by saline solution, albumin and fresh frozen plasma in
equal parts.
Thirteen out of the 15 patients in group I required dialytic
treatment consisting of thrice-weekly, 4 to 5 hour hemodialysis
sessions performed using the same femoral vein and with a plate
hemodialyzer. The blood flow rate was maintained at --250
nil/mm. Eleven out of the 14 group II patients required dialytic
therapy consisting of intermittent pcritoneal dialysis (40 liters
every other day for at least 10 days). The other three group II
patients underwent two or three peritoneal dialysis sessions
during the chemotherapy week.
A low protein, high caloric diet, antiacids and furosemide
were administered to each patient both during treatment and in
the follow-up period,
Follow-up treatment. After a four to six week interval,
prednisone 60 mg/m2/day and cyclophosphamide 100 mg/m2/day
were given orally for four days. This treatment was continued
every month in all the surviving patients for at least six to nine
months regardless of renal function recovery.
Responder patients. Responder patients were considered as
having recovered renal function, evaluated as a fall in serum
creatinine by at least 25%, and as having suspended dialytic
treatment. If serum creatinine had significantly increased during
the follow-up period and/or Bence-Jones proteinuria (BJP) had
risen more than 50% over the level reached by the end of acute
treatment, then group I responder patients would have received
two PE sessions (with or without hemodialysis) while group II
patients would have undergone two penitoneal dialysis sessions.
Non-responder patients. Non responder patients were the
ones whose serum creatinine did not improve or who still
Number of patients
Age, mean SD
Range years
Sex, MIF
K/X
Serum creatinine
mean SD, mgldl
Number of patients requir-
ing dialysis at onset
Number of oliguric patients
Clinical stage at onset:
Group I Group 11
Plasma-exchange group Control group
I I
II 3
III 12 10
Serum /32M
mean
mg/liter
SD 18.7 5.1 8.1 4.7
required dialysis about one month after starting treatment,
They were subsequently treated by CAPD or put on mainte-
nance hemodialysis.
Statistical analysis
Student's t-test and Fisher's exact test were used to assess
the differences between the two groups. P < 0.05 was regarded
as significant. The survival rate of the patients who entered the
study was calculated using Cutler and Ederer's actuarial method
[14]. 'I'he difference between the survival curves was calculated
with the log rank test [15]. All values are expressed as arith-
metical mean SD.
Results
The clinical profile of the patients upon admission is summa-
rized in Table I. There were no statistically significant differ-
ences between the PE group (group I) and the control group
(group II) as regards as sex, age, initial serum creatinine, and
the severity of the disease.
Twenty patients (68.9%) had light chain myelonia (12 kappa
and 8 lambda) while eight had lgG myeloma (5 kappa and 3
lambda) and one IgA (lambda). BJP was present in all cases and
ranged between 1.2 and 13 g/day. The mean values of BJP at the
beginning of the study were similar in the two groups of patients
(group 14.43 0.36 g/day; group II 3.23 0.21 g/day P — NS)
just as they were for the distribution of the very low or the very
high excretors. Twelve of the 29 patients were oliguric (daily
diuresis < 500 ml) at admission, four others became oliguric
shortly after admission, and so oliguria was present in approx-
imately 55% of the cases with an equal distribution in the two
groups. None of the patients showed clinical signs of severe
dehydration or hyperviscosity. Moreover, most patients were
unable to tolerate a high fluid overload because of persistent
oliguria or congestive cardiac failure which were unresponsive
to diuretics. 1-lyperhydration did not modify renal function
quickly in these patients.
Serum calcium levels were less than 12 mg/dl in all cases
except in two patients of group I and in one patient in group II
(12.5, 13.1, 13.9 mg/dI, respectively), serum uric acid concen-
Table 1. Patient characteristics
15
62.86 7.91
(48—73)
10/5
9/6
11.16 3.34
13
8
2
14
63.21 7.0
(50—73)
11/3
8/6
9.23 2.35
II
8
Group I
(plasma-exchange group)
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Fig. 1. Individual follow-up oft/ic two patientgroups. Symbols are: (—) renal failure requiring dialysis; (— — —) renal failure not requiring dialysis;(. . .) serum creatinine <2.5 mg/dl.
tration ranged from 5.5 to 12 mg/dl and total myeloma cell mass
was very high (Stage III) in 75.8%. Renal biopsy was performed
in 17 cases with all but one showing a myeloma cast nephrop-
athy pattern. One group I patient presented protein crystalloid
within the proximal tubular epithelial cells and the tubular
lumina Ill, 12].
Short-term effects of treatment
The individual outcome of the two patient groups is reported
in Figure 1.
During the first two months of treatment (short-term period)
11 out of the 13 group I patients who required hemodialysis
improved renal function. The renal recovery period in fact
ranged from 9 to 34 days after admission. In most of these
patients serum creatinine fell to a level 2.5 mg/dl. The
remaining two non-dialysis-treated patients in group I improved
renal function, reaching a serum creatinine level <2.5 mg/dl
during follow-up. Only one group I patient died within the first
two months of therapy.
Eleven out of the 14 control patients (group 11) required
dialysis. Two of these patients recovered renal function well
enough to stop dialytic treatment (serum creatinirte 5.0and 6.1
mg/dl, respectively). Three patients died within one month and
two more within two months in spite of continued dialysis. The
remaining four patients required long-term dialysis. Thus by the
end of the first two months (Table 2) only 2 of the 11 group II
patients had recovered renal function sufficiently to stop dialy-
sis (46 and 37 days after admission). The remaining three
patients, who did not require dialysis, maintained a stable
serum creatinine level.
Table 2. Short-term effects of therapy in the two groups of patients
Grou p 1 Group 11 P
Number in group 15 14
Number of patients requiring dialysis 13 II NS
Number of patients interrupting II 2 <0.01
dialysis
Number of patients who died within 1 5 NS
the first 2 months
Serum creatinine at the end of the 2.6 2.1 7.7 1.9 <0.001
2nd month mean SD mgldl
In group I BJP decreased dramatically, reaching levels of 0.81
0.46 g/day on the thirtieth day of the study (P < 0.01), while
mean urine output increased significantly (983 721 mI/day at
the beginning of the study vs. 2078 681 mi/day on the 30th
day; P < 0.001). In group II we observed a slight but significant
reduction in light chain excretion on the tenth (2.98 0.19
g/day; P < 0.05) and the thirtieth days (3.25 0.21 g/day; P <
0.05), but without a significant increase in daily diuresis (1235
108 ml/day at the beginning of the study vs. 1450 865 mI/day
on the 30th day). A significant and directly correlated trend was
found between changes in BJP and in serum creatinine (Figure
2) in the individual patient.
Follow-up
Among the three group II patients who did not require
dialysis, one case (No. 13) became progressively oliguric six
months after admission. Thus, after the initial two month
period, five of the nine surviving group II patients required
maintenance dialysis until death for 3, 9, 10, 14 and 16 months
after admission (Fig. 1). The remaining four (2 of whom were
Group!
(control group)
31
101— IiiI —I -it
13' I—It
-I
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Fig. 3. Survival rate of Iot/t patient groups
calculated by the Cutler and Ederer outcome
method. Group I vs. Group 11, P < 0.01.
Symbols are: (•—•) Group I; (A—A) Groupii; (—) cumulative.
responders) continued conservative treatment for a period
ranging from 5 to 21 months. The two responder patients were
both treated with one further cycle of two peritoneal dialysis
sessions necessitated by a significant increase in BJP.
There were 11 responders in the 12 patients who had required
dialysis out of the 14 surviving group I patients. None of the
responders presented any fresh deterioration in renal function
during follow-up. Serum creatinine was stabilized at a level
<2.5 mg/dI in all but two responder patients. In five cases two
PE sessions were repeated once (Nos. 10 and 14), twice (No.
13) or three times (Nos. 5 and 8) because of a significant
increase in BJP from 3 to 12 months following admission. One
non-responder patient was treated on maintenance hernodialy-
sis for seven months. The one-year survival rate was signifi-
cantly higher in group I than in group II patients (Fig. 3).
Moreover, patients who regained renal function had a much
longer survival than those in whom renal function did not
improve. The most frequent causes of death were infections (9
cases) and cancer cachexia or overwhelming tumor (8 cases).
Other causes of death were gastrointestinal bleeding (2 cases),
60
= 0.869 • X —5.713
r0.852 40
P<0.001
0
o0
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—100
0
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Fig. 2. Treatment—induced percentage
changes in BJP correlated to percentage
changes in serumn creatinine ta/ties for the
two groups rf patients. Symbols are: (
Group I patients; (0) Group II patients.
14 14 14
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myocardial infarction (2 cases) and liver insufficiency (I case).
Many patients experienced at least one episode of severe
infection. Early mortality was constant in the ones who devel-
oped an infection within the first month following admission.
Peritonitis developed in only one patient of group II and was
resolved after antibiotic therapy. No patient had signs of uremia
upon death in either of the two groups. Side effects related to
PE were rare and mild.
Discussion
Renal failure represents the most important factor influencing
survival in patients with multiple myeloma [1, 16]. In particular,
acute renal failure or rapidly progressive renal failure rather
than the readily reversible forms of pre-renal azotemia) is
encountered in 7% to 30% of MM patients [1, 5, 6]. Along with
infection, it is held to be the most frequent cause of death in
spite of aggressive dialysis [17, 18]. Many studies have noted
that median survival was only two to three months in MM
patients with severe renal insufficiency [16, 17, 19]. On the
other hand, there have recently been a number of case reports
on renal function recovery and longer survival following acute
renal failure [20, 21]. The latter seems to be favorably managed
by a high fluid intake and alkylating agents with corticosteroids
[22]. Most studies agree, however, that renal function recovery
is unlikely to occur when serum creatinine exceeds 5 mg/dl,
when oliguria is present, and in those patients with light chain
myeloma type [5, 18, 22].
Reports have recently stated that plasmapheresis is an effec-
tive therapy for the removal of circulating light chains, that are
thought to play a major causal role in renal damage due to MM
[7, 13, 23]. A number of studies (8, 9, 10, 20) reported on a few
patients (1, 3, 4, 1, respectively) who significantly improved
renal function after PE treatment associated to corticosteroids
and alkylating agents. We have consequently undertaken a
prospective randomized trial on acute renal failure due to MM
to evaluate the effectiveness of PE in this clinical context. Our
series consisted of 29 patients with MM, 20 of whom had light
chain myeloma and 24 requiring dialytic therapy. Our MM
population is thus one of the largest series of patients presenting
both myeloma and acute renal failure, subsequently undergoing
dialysis. Our patients received identical methylprednisolone
and cyclophosphamide chemotherapy, as these drugs are famil-
iar to nephrologists. In fact methylprednisolone pulses have
proven useful in treating transplant rejection and acute renal
failure due to lupus or cryoglobulinemia. Moreover, the pulses
achieve rapid results and relatively low toxicity, while also
appearing to inhibit osteoclastic activity stimulated by anoma-
lous plasma cells [10, 24].
Combined chemotherapy and peritoneal dialysis has been
claimed to be synergistic in reversing renal injury clue to MM
since peritoneal dialysis may significantly increase light chain
removal [25]. However, some studies have reported good
therapeutic results using this dialytic method in MM patients [5,
21, 26], whereas Cohen et al [201 and Russel et al [27] have not
confirmed the efficacy of peritoneal dialysis in treating MM.
Our study confirms that in severe and acute renal failure due
to MM, a recovery of renal function is rarely achieved with
chemotherapy and peritoneal dialysis. This is at least true when
light chain myeloma with oliguric myeloma cast nephropathy is
present in most cases. In our experience only two out of the 11
group II patients requiring dialysis recovered renal function
well enough to stop treatment. Moreover, mortality was very
high in this group with a 28% survival at 12 months, which is
similar to the figure reported in retrospective studies by De
Fronzo et al [17] and Lazarus et al [181. A more intensive use of
peritoneal dialysis, even continuous, might permit an improved
long-term survival superior to what we have observed in our
series, but this hypothesis has yet to be verified.
As regards the PE group patients there was a marked
correlation between the reduction of light chain proteinuria and
the improvement of renal failure. Eleven out of the 13 patients
requiring dialysis recovered adequate renal function with serum
creatinine falling to a level 2.5 mg/dl in most of them. The
effect on renal function obtained by PE with chemotherapy
persisted for a long time, with no patient requiring further
therapeutic PE owing to a significant increase in serum creati-
nine. The survival rate of PE-treated patients reached 66% at
one year and 53% at two years.
In conclusion, by rapidly removing large amounts of light
chains, PE therapy is a very effective method in the treatment
of acute renal failure due to MM.
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